Prevalence of molecular subtypes and prognosis of invasive breast cancer in north-east of Morocco: Retrospective study

BMC Research Notes

Volumn 5, Issue , 2012, Pages

  Bennis, Sanae ^a   Abbass, Fouad ^b   Akasbi, Yousra ^a   Znati, Kaoutar ^a   Joutei, Khalid Amrani ^b   El Mesbahi, Omar ^a   Amarti, Afaf ^a  

^a HASSAN II UNIVERSITY HOSPITAL   (Morocco)

^b SIDI MOHAMED BEN ABDELLAH UNIVERSITY   (Morocco)

Author keywords

Breast cancer; Disease free Survival (DFS); Molecular subtypes; Overall survival (OS); Prognosis

Indexed keywords

ADULT; ARTICLE; BREAST TUMOR; FEMALE; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MOROCCO; PATHOLOGY; PREVALENCE; PROGNOSIS; RETROSPECTIVE STUDY;

ADULT; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MOROCCO; PREVALENCE; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 84864800884     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-5-436     Document Type: Article

References (25)

1. World Health Organization, Cancer. Fact Sheet No. 297 2006 Available at: http://www.who.int/mediacentre/factsheets/fs297/en/index.html, (accessed 2 August 2007)
2. Molecular portraits of human breast tumours. Perou CM, Sorlie T, Eisen MB, et al. Nature 2000 406 747 752 10.1038/35021093 10963602
3. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Sorlie T, Perou CM, Tibshirani R, et al. Proc Natl Acad Sci U S A 2001 98 10869 10874 10.1073/pnas.191367098 11553815
4. Molecular portraits of breast cancer: tumour subtypes as distinct disease entities. Sorlie T, Eur J Cancer 2004 40 2667 2675 10.1016/j.ejca.2004.08.021 15571950
5. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. Carey LA, Perou CM, Livasy CA, et al. Jama 2006 295 2492 2502 10.1001/jama.295.21.2492 16757721
6. Prevalence, Morphologic Features and Proliferation Indices of Breast Carcinoma Molecular Classes Using Immunohistochemical Surrogate Markers. Bhargava R, Striebel J, Beriwal S, et al. Int J Clin Exp Pathol 2009 2 444 455 19294003
7. Molecular classifications of breast carcinoma with similar terminology and different definitions: are they the same? Tang P, Wang J, Bourne P, Hum Pathol 2008 39 506 513 10.1016/j.humpath.2007.09.005 18289638
8. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer. Wolff AC, Elizabeth M, Hammond H, et al. J Clin Oncol 2007 25 118 145 17159189
9. Cancer prevalence estimates based on tumour registry data in the Surveillance, Epidemiology, and End Results (SEER) program. Merrill RM, Capocaccia R, Feuer EJ, Mariotto A, Int J Epidemiol 2000 29 197 207 10.1093/ije/29.2.197 10817114
10. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Allred DC, Harvey JM, Berardo M, et al. Mod Pathol 1998 11 155 168 9504686
11. Targeted therapy in breast cancer. Ross JS, Fletcher JA, Bloom KJ, et al. Mol & Cell Proteomics 2004 3 379 398 10.1074/mcp.R400001-MCP200 23243479
12. The prevalence of intrinsic subtypes and prognosis in breast cancer patients of different races [abstract]. Junichi K, Takoya M, Takanori I, et al. Breast 2007 16 Suppl 2 72 S77 17714947
13. Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients. Calza S, Hall P, Auer G, et al. Breast Cancer Res 2006 8 suppl 4 34 16846532
14. Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers. Jumppanen M, Gruvberger-Saal S, Kauraniemi P, et al. Breast Cancer Res 2007 9 suppl 1 16 17263897
15. Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival. Fulford LG, Reis-Filho JS, Ryder K, et al. Breast Cancer Res 2007 9 suppl 1 4 17217540
16. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2- negative invasive breast cancer, the so-called triplenegative phenotype. A population-based study from the California Cancer Registry. Bauer KR, Brown M, Cress RD, et al. Cancer 2007 109 1721 1728 10.1002/cncr.22618 17387718
17. Triple negative breast cancers: Clinical and prognostic implications. Dawson SJ, Provenzano E, Caldas C, Eur J Cancer 2009 45 Suppl 1 27 40 19775602
18. The phenotypic spectrum of basal-like breast cancers: a critical appraisal. Fadare O, Tavassoli FA, Adv Anat Pathol 2007 14 Suppl 5 358 373 17717437
19. Prognostic markers in triple-negative breast cancer. Rakha EA, El-Sayed ME, Green AR, et al. Cancer 2007 109 Suppl 1 25 32 17146782
20. Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. Tischkowitz M, Brunet JS, Begin LR, et al. BMC Cancer 2007 7 134 10.1186/1471-2407-7-134 17650314
21. Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast. Fulford LG, Easton DF, Reis-Fiho JS, et al. Histopathology 2006 49 22 34 10.1111/j.1365-2559.2006.02453.x 16842243
22. The basal subtype of breast carcinomas may represent the group of breast tumors that could benefit from EGFR-targeted therapies. Siziopikou KP, Cobleigh M, Breast 2007 16 104 107 10.1016/j.breast.2006.09.003 17097880
23. Molecular classification system identifies invasive breast carcinoma patients who are most likely and those who are least likely to achieve a complete pathologic response after neoadjuvant chemotherapy. Goldestein S, Decker D, Severson D, et al. Cancer 2007 110 1687 1696 10.1002/cncr.22981 17722109
24. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Carey LA, Dees EC, Sawyer L, et al. Clin Cancer Res 2007 13 2329 2334 10.1158/1078-0432.CCR-06-1109 17438091
25. Molecular Classification of Breast Carcinomas by Immunohistochemical Analysis. Tang P, Skinner KA, Hicks DG, Diagn Mol Pathol 2009 18 125 132 10.1097/PDM.0b013e31818d107b 19704256